NCT02615054View on ClinicalTrials.gov

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

CompletedOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

March 5, 2024

Study Completion Date

March 5, 2024

Conditions
Trastuzumab CardiotoxicityHER2-Positive Breast Cancer Survivors
Interventions
DEVICE

2D Echocardiogram

All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.

DEVICE

Cardiopulmonary exercise testing and post-CPET cardiac function

To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02615054 - Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors | Biotech Hunter | Biotech Hunter